24/7 Market News Snapshot 08 January, 2025 – Biofrontera Inc. Common Stock (NASDAQ:BFRI)

January 8, 2025

DENVER, Colo., 08 January, 2025 (247marketnews.com) – (NASDAQ:BFRI) are discussed in this article.
Biofrontera Inc. has experienced a remarkable surge in its stock price, opening at $1.11 and rising to $1.341, which represents an impressive increase of 20.81%. This substantial growth follows a closing price of $1.110 and has generated significant investor interest, as evidenced by a current trading volume of 7.30 million shares. Analysts are noting bullish momentum in the stock’s performance, with many investors keenly observing the potential for continued upward movement.

In addition to its stock performance, Biofrontera has achieved a pivotal milestone in its Phase 3 study focusing on the use of Ameluz in conjunction with RhodoLED photodynamic therapy for the treatment of superficial basal cell carcinoma (sBCC). As of December 2024, the final patient has completed a one-year follow-up visit in the trial (ALA-BCC-CT013), thereby facilitating the company’s preparations for a submission to the FDA, projected for the third quarter of 2025.

This double-blind, randomized, placebo-controlled study involved 187 participants and aimed to assess the safety and effectiveness of Ameluz-PDT compared to a placebo. The findings yielded statistically significant results for both primary and secondary endpoints (p < 0.0001), emphasizing Ameluz’s potential in successfully treating sBCC. Dr. Hermann Luebbert, CEO and Chairman of Biofrontera, remarked on the significance of this progress, noting that sBCC is the most common form of skin cancer, with millions of cases diagnosed annually. The completion of the one-year follow-up represents a critical step towards obtaining FDA approval and enhancing treatment options for patients facing this disease. As Biofrontera prepares for its next regulatory steps, it remains committed to delivering innovative treatment solutions in dermatology, while building strong partnerships within the healthcare sector to better serve the needs of patients suffering from skin cancer.

Related news for (BFRI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.